Projects per year
Abstract
In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.
Original language | English |
---|---|
Pages (from-to) | 76-78 |
Number of pages | 3 |
Journal | Nature Reviews. Gastroenterology & Hepatology |
Volume | 14 |
Issue number | 2 |
Early online date | 11 Jan 2017 |
DOIs | |
Publication status | Published - Feb 2017 |
Keywords
- obeticholic acid
- Primary biliary cholangitis
- cholangiocytes
- Cholestatic liver disease
- biliary
Fingerprint
Dive into the research topics of 'Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances'. Together they form a unique fingerprint.Projects
- 1 Finished
-
The roles and control of CD4+ effector and regulatory T-cells in biliary autoimmunity
Webb, G.
8/09/14 → 7/09/17
Project: Research Councils